159 related articles for article (PubMed ID: 21772092)
1. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
[TBL] [Abstract][Full Text] [Related]
2. Predictors of response to targeted therapy in renal cell carcinoma.
Eisengart LJ; MacVicar GR; Yang XJ
Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
[TBL] [Abstract][Full Text] [Related]
3. [Biomarker for molecular targeting therapy against renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2012 Jan; 39(1):39-42. PubMed ID: 22454982
[No Abstract] [Full Text] [Related]
4. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
5. Sequential use of targeted agents in the treatment of renal cell carcinoma.
Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.
Procopio G; Verzoni E; Iacovelli R; Guadalupi V; Gelsomino F; Buzzoni R
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1631-40. PubMed ID: 22050012
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
8. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
[TBL] [Abstract][Full Text] [Related]
9. [Molecular targeted therapy for advanced renal cell carcinoma].
Kanayama H
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in clear cell renal cell carcinoma.
George S; Bukowski RM
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1737-47. PubMed ID: 18062748
[TBL] [Abstract][Full Text] [Related]
11. [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
Tomita Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):907-10. PubMed ID: 21677480
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.
Bex A; Gore M; Mulders P; Sternberg CN
BJU Int; 2012 Nov; 110(9):1289-300. PubMed ID: 22624610
[TBL] [Abstract][Full Text] [Related]
13. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
Leroy X; Edeline J; Rioux-Leclercq N
Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
[TBL] [Abstract][Full Text] [Related]
14. [Renal cell carcinoma-response criteria of molecular targeted therapy and the timing of sequential drugs in patients with advanced renal cell carcinoma].
Shinohara N
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1462-6. PubMed ID: 23064056
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy of renal cell cancer.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma.
Rathmell WK; Martz CA; Rini BI
Curr Opin Oncol; 2007 May; 19(3):234-40. PubMed ID: 17414642
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
19. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
20. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
